{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/32919"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/32919","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"Therapeutic Role of Follistatin in Hypertension","abstract":"Hypertension is a leading cause of morbidity and mortality worldwide. 1 in 5 Canadians have hypertension and a third of this population have uncontrolled high blood pressure (BP) even while on commonly prescribed antihypertensive treatments. Majority of hypertensive patients have high BP that develops from an unknown cause termed primary or essential hypertension. This is characterized by remodeling of small arteries called resistance vessels which is driven in part by oxidative stress. Most vessels are surrounded by perivascular adipose tissue (PVAT) which regulates vascular tone via release of vasoactive substances. In physiological conditions, PVAT releases more relaxing factors, promoting vasodilation. This anticontractile effect is reduced in hypertension due to elevated oxidative stress. Follistatin, an endogenous inhibitor of activins, reduces oxidative stress and induces adipose tissue browning – the conversion of white to brown adipose tissue – which is a process linked to improved vasorelaxation and lower blood pressure. Whether follistatin affects PVAT is unknown. We hypothesize that follistatin, through the amelioration of PVAT structure and function, improves vascular function and BP in a model of essential hypertension. In our first study, we demonstrated that follistatin lowered blood pressure in models of essential and secondary hypertension. Follistatin improved resistance vessel structure evidenced by reduced reactive oxygen species (ROS) and fibrosis. Vascular contraction was decreased and relaxation was improved by follistatin at least in part by the inhibition of ROS and activin A. Our second study investigated the effects of follistatin on the regulation of vascular function by PVAT. We discovered that follistatin treatment reduced ROS and increased markers of brown adipose tissue in PVAT around resistance vessels. Additionally, follistatin increased bioavailability and production of nitric oxide, a vasodilator, in PVAT through ROS inhibition. We describe mechanisms underlying these processes including the neutralization of activins and phosphorylation of AMPK in PVAT which restored its anticontractile effect. BP reduction alone using hydralazine, does not replicate beneficial effects on PVAT-mediated vascular function suggesting that follistatin directly affects PVAT to induce these effects. Our studies collectively demonstrate that follistatin effectively lowers BP and improves vascular function in both essential and secondary hypertension. Follistatin ameliorates vascular function through direct effects on PVAT highlighting the therapeutic potential of targeting PVAT and vascular function in the management of hypertension.","abstract_html":"Hypertension is a leading cause of morbidity and mortality worldwide. 1 in 5 Canadians have hypertension and a third of this population have uncontrolled high blood pressure (BP) even while on commonly prescribed antihypertensive treatments. Majority of hypertensive patients have high BP that develops from an unknown cause termed primary or essential hypertension. This is characterized by remodeling of small arteries called resistance vessels which is driven in part by oxidative stress. Most vessels are surrounded by perivascular adipose tissue (PVAT) which regulates vascular tone via release of vasoactive substances. In physiological conditions, PVAT releases more relaxing factors, promoting vasodilation. This anticontractile effect is reduced in hypertension due to elevated oxidative stress. Follistatin, an endogenous inhibitor of activins, reduces oxidative stress and induces adipose tissue browning – the conversion of white to brown adipose tissue – which is a process linked to improved vasorelaxation and lower blood pressure. Whether follistatin affects PVAT is unknown. We hypothesize that follistatin, through the amelioration of PVAT structure and function, improves vascular function and BP in a model of essential hypertension. In our first study, we demonstrated that follistatin lowered blood pressure in models of essential and secondary hypertension. Follistatin improved resistance vessel structure evidenced by reduced reactive oxygen species (ROS) and fibrosis. Vascular contraction was decreased and relaxation was improved by follistatin at least in part by the inhibition of ROS and activin A. Our second study investigated the effects of follistatin on the regulation of vascular function by PVAT. We discovered that follistatin treatment reduced ROS and increased markers of brown adipose tissue in PVAT around resistance vessels. Additionally, follistatin increased bioavailability and production of nitric oxide, a vasodilator, in PVAT through ROS inhibition. We describe mechanisms underlying these processes including the neutralization of activins and phosphorylation of AMPK in PVAT which restored its anticontractile effect. BP reduction alone using hydralazine, does not replicate beneficial effects on PVAT-mediated vascular function suggesting that follistatin directly affects PVAT to induce these effects. Our studies collectively demonstrate that follistatin effectively lowers BP and improves vascular function in both essential and secondary hypertension. Follistatin ameliorates vascular function through direct effects on PVAT highlighting the therapeutic potential of targeting PVAT and vascular function in the management of hypertension.","abstract_has_math":false,"creators":["Kuganathan, Ann"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Krepinsky, Joan"],"committee_chairs":[],"committee_members":[],"year":2026,"date_issued":"2026","date_published":"2026","updated_at":"2026-11-18T19:33:16Z","subjects":["Essential hypertension","Follistatin","Activin","Perivascular adipose tissue","Vascular"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/13659"],"render_values":[{"text":"https://doi.org/10.71548/13659","href":"https://doi.org/10.71548/13659","code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/11375/32919","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/11375/32919","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F32919","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Krepinsky, Joan"]},{"key":"dc:creator","label":"Author","values":["Kuganathan, Ann"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2026-03-25T18:42:17Z"]},{"key":"dc:date.issued","label":"Date","values":["2026"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Essential hypertension","Follistatin","Activin","Perivascular adipose tissue","Vascular"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/11375/32919","https://doi.org/10.71548/13659"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Hypertension is a leading cause of morbidity and mortality worldwide. 1 in 5 Canadians have hypertension and a third of this population have uncontrolled high blood pressure (BP) even while on commonly prescribed antihypertensive treatments. Majority of hypertensive patients have high BP that develops from an unknown cause termed primary or essential hypertension. This is characterized by remodeling of small arteries called resistance vessels which is driven in part by oxidative stress. Most vessels are surrounded by perivascular adipose tissue (PVAT) which regulates vascular tone via release of vasoactive substances. In physiological conditions, PVAT releases more relaxing factors, promoting vasodilation. This anticontractile effect is reduced in hypertension due to elevated oxidative stress. Follistatin, an endogenous inhibitor of activins, reduces oxidative stress and induces adipose tissue browning – the conversion of white to brown adipose tissue – which is a process linked to improved vasorelaxation and lower blood pressure. Whether follistatin affects PVAT is unknown. We hypothesize that follistatin, through the amelioration of PVAT structure and function, improves vascular function and BP in a model of essential hypertension. In our first study, we demonstrated that follistatin lowered blood pressure in models of essential and secondary hypertension. Follistatin improved resistance vessel structure evidenced by reduced reactive oxygen species (ROS) and fibrosis. Vascular contraction was decreased and relaxation was improved by follistatin at least in part by the inhibition of ROS and activin A. Our second study investigated the effects of follistatin on the regulation of vascular function by PVAT. We discovered that follistatin treatment reduced ROS and increased markers of brown adipose tissue in PVAT around resistance vessels. Additionally, follistatin increased bioavailability and production of nitric oxide, a vasodilator, in PVAT through ROS inhibition. We describe mechanisms underlying these processes including the neutralization of activins and phosphorylation of AMPK in PVAT which restored its anticontractile effect. BP reduction alone using hydralazine, does not replicate beneficial effects on PVAT-mediated vascular function suggesting that follistatin directly affects PVAT to induce these effects. Our studies collectively demonstrate that follistatin effectively lowers BP and improves vascular function in both essential and secondary hypertension. Follistatin ameliorates vascular function through direct effects on PVAT highlighting the therapeutic potential of targeting PVAT and vascular function in the management of hypertension."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Doctor of Philosophy (PhD)"]},{"key":"dc:title","label":"Title","values":["Therapeutic Role of Follistatin in Hypertension"]},{"key":"dc:title.alternative","label":"Alternative Title","values":["Regulation of Vascular Function by Follistatin in Hypertension"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["Krepinsky, Joan"],"dc:creator":["Kuganathan, Ann"],"dc:date.accessioned":["2026-03-25T18:42:17Z"],"dc:date.issued":["2026"],"dc:description.abstract":["Hypertension is a leading cause of morbidity and mortality worldwide. 1 in 5 Canadians have hypertension and a third of this population have uncontrolled high blood pressure (BP) even while on commonly prescribed antihypertensive treatments. Majority of hypertensive patients have high BP that develops from an unknown cause termed primary or essential hypertension. This is characterized by remodeling of small arteries called resistance vessels which is driven in part by oxidative stress. Most vessels are surrounded by perivascular adipose tissue (PVAT) which regulates vascular tone via release of vasoactive substances. In physiological conditions, PVAT releases more relaxing factors, promoting vasodilation. This anticontractile effect is reduced in hypertension due to elevated oxidative stress. Follistatin, an endogenous inhibitor of activins, reduces oxidative stress and induces adipose tissue browning – the conversion of white to brown adipose tissue – which is a process linked to improved vasorelaxation and lower blood pressure. Whether follistatin affects PVAT is unknown. We hypothesize that follistatin, through the amelioration of PVAT structure and function, improves vascular function and BP in a model of essential hypertension. In our first study, we demonstrated that follistatin lowered blood pressure in models of essential and secondary hypertension. Follistatin improved resistance vessel structure evidenced by reduced reactive oxygen species (ROS) and fibrosis. Vascular contraction was decreased and relaxation was improved by follistatin at least in part by the inhibition of ROS and activin A. Our second study investigated the effects of follistatin on the regulation of vascular function by PVAT. We discovered that follistatin treatment reduced ROS and increased markers of brown adipose tissue in PVAT around resistance vessels. Additionally, follistatin increased bioavailability and production of nitric oxide, a vasodilator, in PVAT through ROS inhibition. We describe mechanisms underlying these processes including the neutralization of activins and phosphorylation of AMPK in PVAT which restored its anticontractile effect. BP reduction alone using hydralazine, does not replicate beneficial effects on PVAT-mediated vascular function suggesting that follistatin directly affects PVAT to induce these effects. Our studies collectively demonstrate that follistatin effectively lowers BP and improves vascular function in both essential and secondary hypertension. Follistatin ameliorates vascular function through direct effects on PVAT highlighting the therapeutic potential of targeting PVAT and vascular function in the management of hypertension."],"dc:description.degree":["Doctor of Philosophy (PhD)"],"dc:identifier.uri":["https://hdl.handle.net/11375/32919","https://doi.org/10.71548/13659"],"dc:language.iso":["en"],"dc:subject":["Essential hypertension","Follistatin","Activin","Perivascular adipose tissue","Vascular"],"dc:title":["Therapeutic Role of Follistatin in Hypertension"],"dc:title.alternative":["Regulation of Vascular Function by Follistatin in Hypertension"],"dc:type":["Thesis"],"others:access_status":["open.access"]},"updated_at":"2026-11-18T19:33:16Z"}